Sign up online today & collaborate
or click here to find out more
Just after Theravectys’ announcement about its phase I/II success, InnaVirVax completed a third funding round to accelerate its Phase 2 clinical development. The first-in-class immunotherapy designed to treat HIV infections gained further support by all the historical investors in the company.
Since 1987, HIV has mainly been treated with a combination of distinct antiretrovirals. These drugs efficiently reduce HIV levels in the blood and prevent the disease from breaking out for many years. However, this therapy can’t completely eradicate the virus. The immune system remains active and patients frequently suffer from chronic inflammation processes that can cause secondary diseases.
For more click here